Dasatinib
Treatment for Chronic Myeloid Leukemia
Typical Dosage: 100 mg daily
Effectiveness
92%
Safety Score
60%
Clinical Trials
142
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
100 mg daily
Time to Effect
1-3 months for initial molecular response
Treatment Duration
Lifetime (or 5+ years for TFR attempts)
Evidence Quality
HIGHConfidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$2,000
Side Effect Mgmt:$1,500
Total Annual:$123,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
11
Outcome-Based Costs
Cost per Responder
$154,375
Cost per Remission
$247,000
Comparison vs Imatinib (generic)
Cost Difference
+$112,750/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Dasatinib Outcomes
for Chronic Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+80%
Remission Rate
+50%
Common Side Effects
Fluid retention (pleural effusion, peripheral edema)
+45%
Myelosuppression
+35%
Diarrhea
+35%
Headache
+25%
Nausea
+25%
Fatigue
+25%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
14 completed trials for Dasatinib in Chronic Myeloid Leukemia
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
NCT00337454COMPLETEDPHASE1, PHASE2
48 participants
INTERVENTIONAL
Nagoya, Japan +20 more
Started: Jul 1, 2005
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
NCT03625388COMPLETEDPHASE2
56 participants
INTERVENTIONAL
Amman, Jordan +4 more
Started: Nov 5, 2018
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
NCT01804985COMPLETEDPHASE2
174 participants
INTERVENTIONAL
Liverpool, United Kingdom
Started: Dec 1, 2013
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
NCT00101647COMPLETEDPHASE2
197 participants
INTERVENTIONAL
Birmingham, United States +69 more
Started: Dec 1, 2004
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
NCT00123474COMPLETEDPHASE3
724 participants
INTERVENTIONAL
Birmingham, United States +136 more
Started: Jul 1, 2005
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
NCT00482703COMPLETEDPHASE1, PHASE2
23 participants
INTERVENTIONAL
Nagoya, Japan +8 more
Started: May 1, 2007
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
NCT05286528COMPLETED
1.48K participants
OBSERVATIONAL
Budapest, Hungary
Started: Nov 18, 2020
A Bioequivalence Study of Dasatinib Tablet
NCT05640804COMPLETEDPHASE1
56 participants
INTERVENTIONAL
Changchun, China
Started: Sep 9, 2018
Dasatinib Holiday for Improved Tolerability
NCT02890784COMPLETEDPHASE3
291 participants
INTERVENTIONAL
Aachen, Germany +52 more
Started: Aug 1, 2016
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
NCT00866736COMPLETEDPHASE2
65 participants
INTERVENTIONAL
Bunkyo-ku, Japan
Started: Mar 1, 2009
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
NCT01342679COMPLETEDPHASE2
21 participants
INTERVENTIONAL
Bunkyo-ku, Japan
Started: Apr 1, 2011
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
NCT04925141COMPLETEDPHASE4
62 participants
INTERVENTIONAL
Shenzhen, China +3 more
Started: May 10, 2016
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
NCT02326311COMPLETEDPHASE3
229 participants
INTERVENTIONAL
Milan, Italy
Started: Jun 10, 2015
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
NCT00101660COMPLETEDPHASE2
387 participants
INTERVENTIONAL
Anaheim, United States +84 more
Started: Feb 1, 2005
Showing 20 of 143 total trials